Biologic & Biosimilar RA Drugs Market Set To Grow From $15.55 Billion In 2026 To $20.52 Billion By 2030 At A CAGR Of 7.2%
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Biologic & Biosimilar RA Drugs Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for biologic and biosimilar rheumatoid arthritis drugs has expanded significantly in recent years. Projected to rise from $14.57 billion in 2025 to $15.55 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 6.8%. Historical expansion was driven by factors such as the increasing occurrence of rheumatoid arthritis, a scarcity of therapeutic alternatives, heightened funding for biologic research, growing healthcare spending, and the expiration of patents on major biologic products.
Over the upcoming years, the market for biologic and biosimilar rheumatoid arthritis drugs is anticipated to experience robust expansion. Projections indicate it will reach $20.53 billion by 2030, with a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the forecast period is driven by factors such as the rising acceptance of biosimilars, innovations in drug delivery technologies, increased production capabilities, regulatory frameworks that support biologics, and heightened awareness of precision medicine. Key developments shaping the forecast period encompass the emergence of personalized biologic treatments, a faster uptake of biosimilars, cutting-edge drug delivery systems, greater regulatory alignment for biologics, and strategies to reduce costs in managing rheumatoid arthritis.
Download A Free Sample Report For Comprehensive Market Insights:
Biologic & Biosimilar RA Drugs Market Growth Factors Supporting Long-Term Expansion
The growth of the biologic and biosimilar rheumatoid arthritis drug market is anticipated to advance, fueled by rising healthcare expenditures. Healthcare spending denotes the overall financial outlay by governments, individuals, and organizations on medical goods and services, covering costs associated with preventing, treating, and managing health conditions. Within this context, biologic and biosimilar RA drugs enhance the management of rheumatoid arthritis by effectively balancing therapeutic benefits with cost efficiency, particularly in delivering the specialized and costly treatments that healthcare spending often entails. For example, as reported by the CIHI, a health information institute based in Canada, in November 2023, national health spending is projected to hit $344 billion in 2023—equivalent to $8,740 per Canadian—reflecting a 2.8% increase that year, following a modest 1.5% rise in 2022. Consequently, the continual escalation of healthcare spending is propelling the biologic and biosimilar RA drug market forward.
Biologic & Biosimilar RA Drugs Market Segmentation Trends And Revenue Drivers
The biologic & biosimilar ra drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Manufacturing: Outsourced, In-House
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
Biologic & Biosimilar RA Drugs Market Industry Trends Shaping Future Revenue Growth
Major players in the biologic and biosimilar RA drugs market are actively concentrating on the development of cutting-edge solutions like dual-concentration biosimilar formulations, specifically to address the growing need for affordable, easily accessible, and patient-friendly options that serve as alternatives to expensive biologics. These dual-concentration biosimilar products offer both high- and low-strength formulations designed to closely replicate branded biologics, which facilitates uninterrupted treatment continuity and enhances patient convenience compared to standard single-concentration biologics. To illustrate, in July 2023, HADLIMA—a biosimilar of Humira (adalimumab)—was launched in the US through a collaboration between Organon, a US healthcare company, and Samsung Bioepis, a biopharmaceutical firm based in South Korea. Available in both high and low concentrations, HADLIMA is intended to improve access and affordability for individuals managing autoimmune diseases, and it is priced at an 85% discount relative to Humira, thereby supporting broader patient access. This biosimilar includes an autoinjector endorsed by the Arthritis Foundation, alongside a patient support initiative known as HADLIMA For You, which offers educational materials and co-pay assistance. HADLIMA is indicated for a range of conditions, including rheumatoid arthritis and Crohn’s disease, and it is offered in both a citrate-free high-concentration version (100 mg/mL) and a citrate-containing low-concentration version (50 mg/mL), ensuring patients experience seamless continuity in their care.
Biologic & Biosimilar RA Drugs Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the biologic & biosimilar ra drugs market are Samsung BioLogics Co. Ltd., Amgen Inc., AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.
Access The Complete Biologic & Biosimilar RA Drugs Market Report:
Biologic & Biosimilar RA Drugs Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the biologic & biosimilar RA drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
